Cormorant Asset Management, LP's Net Worth

$130 Million

Who is Cormorant Asset Management, LP?

Cormorant Asset Management, LP has an estimated net worth of $130 Million. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., Turning Point Therapeutics, Inc., Vigil Neuroscience, Inc., Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Kezar Life Sciences, Inc., Icosavax, Inc., Atea Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Ventyx Biosciences, Inc., Axonics Modulation Technologies, Inc., Tyra Biosciences, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., Apellis Pharmaceuticals, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., PROTEOSTASIS THERAPEUTICS, INC., BioAtla, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Akouos, Inc., Cellectar Biosciences, Inc., Olema Pharmaceuticals, Inc., Clearside Biomedical, Inc., GreenLight Biosciences Holdings, PBC, CONSTELLATION PHARMACEUTICALS INC, MoonLake Immunotherapeutics, and EyePoint Pharmaceuticals, Inc..

SEC CIK

Cormorant Asset Management, LP's CIK is 0001583977

Past Insider Trading and Trends

2017 was Cormorant Asset Management, LP's most active year for acquiring shares with 2 total transactions. Cormorant Asset Management, LP's most active month to acquire stocks was the month of October. 2018 was Cormorant Asset Management, LP's most active year for disposing of shares, totalling 5 transactions. Cormorant Asset Management, LP's most active month to dispose stocks was the month of May. 2017 saw Cormorant Asset Management, LP paying a total of $14,999,992.00 for 3,473,925 shares, this is the most they've acquired in one year. In 2017 Cormorant Asset Management, LP cashed out on 2,402,497 shares for a total of $0.00, their largest year based on trade value.